Home | Contact Us 

Online Catalog

View our online catalog.
For further information or for a quotation, call 1-510-475-0650 or email us at

How Can We Help You?
Click here to contact us!


Sepragen Announces Senior Management Addition

Union City, CA, December 19, 2000 -- Sepragen Corporation (OTC BB: SPGNA), a provider of patented technology and equipment for purification needs in the nutritional and biotech industries, today announced the addition of Henry "Skip" Edmunds, Ph. D., as acting CFO. Dr. Edmunds, who is currently a board member, will take on a more active role in the oversight of the financial activities of the Company and participate in raising of capital and structuring deals and alliances. Dr. Edmunds has served as CFO at two biotech companies - Sangstat and Prometheus - and prior to that was Director of Business Development and Financial Planning at Genencor. He has a Ph. D. in Biochemistry from the University of California at Berkeley and an MBA from Stanford University. In an unrelated event, the Company is replacing its auditors, Grant Thornton, with Bedinger & Company. Grant Thornton had recently resigned from Sepragen. The resignation was not due to any disagreement on any matter of accounting principles, financial statement disclosures or auditing scope or procedure.

Of these changes, Vinit Saxena, Sepragen's CEO, said, "Dr. Edmund's addition will help us implement financial systems and provide support for financial analyses to make sound decisions for growth. Changing our accountants to a smaller firm provides us with both the benefits of economy along with more responsiveness that we need in order to operate as a reporting public company."

Sepragen is a leading supplier of separation process technology, equipment and consumables to the biotechnology and nutraceutical industries. In addition to its biotech drug separation business, the Company has developed patented applications that provide large market opportunities in the food and beverage industry, including debittering citrus juices, extracting isoflavone (plant estrogen) from soy as well as extracting proteins from whey. The Company holds over 14 issued patents relating to its core technology.

Return to News Archives main page

The statements in this release that relate to future events or performance, statements about growth, future regulatory clearances, levels of sales and market size and future manufacturing capacity and efficiencies are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to the development of markets for and commercial acceptance of the company's products and services, the availability of components, competitors' product introductions and other risks identified in the company's SEC filings. Actual results may differ from those described in these forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof.

Company | Products | News and Events | Contact Us | Terms and Conditions | Privacy Policy © 2020 Sepragen Corporation. All rights reserved. (510) 475-0650